CD137激动可重编程人单核/巨噬细胞代谢与功能并增强其杀瘤活性
该研究探讨CD137在人单核/巨噬细胞中的作用,发现CD137在健康对照单核细胞表达,在多发性骨髓瘤或慢性淋巴细胞白血病患者中表达更高。CD137高表达单核细胞具有独特表型、转录组和代谢特征,吞噬能力增强,对经抗CD38或抗CD20单抗处理的多发性骨髓瘤和淋巴瘤细胞具有更强的抗体依赖性吞噬作用。CD137激动通过ERK依赖方式促进代谢和杀瘤活性,并诱导M1样表型偏斜。
要点
- CD137在健康对照及骨髓瘤/CLL患者单核细胞表达,患者中更高。
- CD137高表达单核细胞吞噬能力增强,ADPC对骨髓瘤和淋巴瘤细胞更强。
- CD137激动经ERK依赖方式增强代谢与杀瘤活性,诱导M1样偏斜。
核心结论
- CD137是人单核/巨噬细胞的阳性免疫检查点,激动后可增强其杀瘤活性。
- CD137激动与肿瘤靶向抗体联用可能具有协同治疗潜力。
研究设计与样本
- 研究比较健康对照与多发性骨髓瘤或CLL患者单核细胞CD137表达。
- 对CD137高表达单核细胞进行表型、转录组和代谢分析及功能实验。
主要发现
- CD137在健康对照单核细胞表达,在多发性骨髓瘤或CLL患者中表达更高。
- CD137高表达单核细胞具有独特表型、转录组和代谢特征。
- CD137高表达单核细胞吞噬能力增强,对经抗CD38或抗CD20单抗处理的多发性骨髓瘤和淋巴瘤细胞ADPC更强。
- CD137激动以ERK依赖方式促进代谢和杀瘤活性,并诱导M1样表型偏斜。
临床怎么用
- CD137激动剂与肿瘤靶向抗体联用可能增强对骨髓瘤和淋巴瘤的杀伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapies have heralded a new era in the cancer treatment. In addition to checkpoint inhibitors, agonistic antibodies against co-stimulatory immune receptors hold the potential to invoke efficient antitumor immunity. Targeting CD137 has gained momentum based on its ability to drive NK- and T-cell-based responses. CD137-engaging mAbs have already entered clinical trials for different types of tumors showing promising results. Despite the efforts to translate CD137-mediated immunotherapy into clinical practice, little remains known regarding the role of CD137 in human monocytes/macrophages.We found CD137 being expressed on monocytes of healthy controls and at even higher levels in patients with multiple myeloma or CLL. CD137HI(GH) monocytes displayed a distinct phenotypic, transcriptomic, and metabolic profile. They possessed an increased phagocytic capacity enabling superior antibody-dependent phagocytosis (ADPC) of multiple myeloma and lymphoma cells that were treated with anti-CD38 or anti-CD20 mAbs. Triggering CD137 promoted both metabolic and tumoricidal activity in an extracellular signal-regulated kinase (ERK)-dependent fashion. In addition, we observed a phenotypic, transcriptomic, and functional skewing towards a M1-like phenotype.Overall, we introduce CD137 as a positive immune checkpoint on human monocytes/macrophages, which can have therapeutic implications especially in view of synergistic effects when combining CD137 agonists with tumor-targeting antibodies.
引用
- Stoll A, Bruns H, Fuchs M, et al. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia. 2021. PMID: 34021248. doi:10.1038/s41375-021-01287-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。